Anavex to Present Full Phase 1 Clinical Trial Data for ANAVEX 2-73 at CNS Summit 2014 Conference
NEW YORK, NY, November 10, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS), and various types of cancer, is pleased to announce the upcoming presentation of complete Phase 1 clinical trial data for ANAVEX 2-73. The data will be revealed in a poster session at CNS Summit 2014 on November 14th. The poster was co-authored by Ole Voges and Ingo Weigmann of ABX-CRO, Norman Bitterlich of Medizin & Service GmbH, Christoph Schindler of Clinical Research Center, and Christopher U. Missling, President and CEO of Anavex.
The full Phase 1 findings will be presented as follows:
|Title:||A Phase 1 Dose Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of ANAVEX 2-73 in Healthy Male Subjects|
|Date:||Friday, November 14, 2014|
|Time:||5:00 PM – 7:00 PM ET|
|Place:||The Boca Raton Waldorf Astoria,
501 East Camino Real, Boca Raton, FL 33432
Complete Phase 1 data will be reported by Anavex in a news release following the poster presentation.
With recent regulatory approval of ANAVEX 2-73 for a Phase 2a clinical trial, the Phase 1 data presentation will come at a key time for Anavex. ANAVEX 2-73, the Company’s lead proprietary compound, is an orally available small molecule being investigated for the treatment of Alzheimer’s disease. The compound targets sigma-1 and muscarinic receptors, which have shown in preclinical studies to reduce the stress levels in the brain and to reverse the pathological hallmarks observed in Alzheimer’s.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (OTCQB: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat Alzheimer’s disease, other Central Nervous System (CNS) diseases, and various types of cancer. Anavex’s lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®), are currently in a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean data profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. The drug combination ANAVEX PLUS produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. Further information is available at www.anavex.com.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information
Anavex Life Sciences Corp.
Research & Business Development